Jul 22, 2021 1:15 PM

Volition's Nu.Q® NETs Assay Demonstrates Promising Results in COVID-19 Risk Stratification and Disease Monitoring

May 11, 2021 9:15 PM

VolitionRx Limited Announces First Quarter 2021 Financial Results and Business Update

May 06, 2021 1:30 PM

VolitionRx Limited Schedules First Quarter 2021 Earnings Conference Call and Business Update

Mar 31, 2021 1:45 PM

VolitionRx Limited Announces Publication of Significant Nu.Q® Capture Mass Spectrometry Paper

Mar 30, 2021 1:45 PM

VolitionRx Limited Appoints Dr. Tom Butera DVM as Chief Executive Officer for Volition Veterinary Subsidiary

Mar 29, 2021 9:15 PM

VolitionRx Limited Appoints Two New Directors

Mar 22, 2021 8:15 PM

VolitionRx Limited Announces Full Fiscal Year 2020 Financial Results and Business Update

Mar 17, 2021 12:15 PM

New Data Demonstrates Nu.Q® is Effective in Monitoring Treatment of Sepsis

Mar 16, 2021 12:45 PM

VolitionRx Limited Schedules Full Fiscal Year 2020 Earnings Conference Call and Business Update

Mar 08, 2021 9:30 PM

VolitionRx Limited to Present at Conferences in March 2021

Feb 12, 2021 2:30 PM

VolitionRx Limited Announces Closing of $20 Million Underwritten Public Offering of Common Stock

Feb 10, 2021 2:30 PM

VolitionRx Limited Announces Pricing of $20 Million Underwritten Public Offering of Common Stock

Feb 09, 2021 9:15 PM

VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock

Feb 02, 2021 1:00 PM

VolitionRx Provides a Business Update and Appoints Key Officers to Drive Commercialization Efforts

Jan 28, 2021 11:30 AM

National Taiwan University Hospital Presents Data on Nu.Q™ Assay Performance at the World Conference on Lung Cancer

Jan 25, 2021 2:00 PM

VolitionRx Limited Opens its New Manufacturing Facility in Belgium

Jan 06, 2021 1:30 PM

Press Releases